Leaders | Ideology versus prosperity

How Xi Jinping is damaging China’s economy

Inflexible policies are trumping pragmatism

Over the past 20 years China has been the biggest and most reliable source of growth in the world economy. It contributed a quarter of the rise in global gdp over that period and expanded in 79 of 80 quarters. For most of the period since China opened up after Mao’s death, the Communist Party has taken a practical approach to making the country richer, mixing market reforms with state control. Now, however, China’s economy is in danger. The immediate issue is its zero-covid campaign, which has caused a slump and may condemn the economy to a stop-start pattern. That is compounding a bigger problem: President Xi Jinping’s ideological struggle to remake state capitalism. If it stays on this path China will grow more slowly and be less predictable, with big consequences for it and the world.

This article appeared in the Leaders section of the print edition under the headline “Ideology versus prosperity”

China’s slowdown

From the May 28th 2022 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Leaders

Keir Starmer surrounded by the Eu stars

Sir Keir Starmer should aim higher in his reset with the EU

And he needs to be clearer about what Britain wants

illustration of a world map outlined by a single red electrical cord, with a plug at one end and a socket at the other

To make electricity cheaper and greener, connect the world’s grids

Less than 3% of the world’s power is internationally traded—a huge wasted opportunity


Chinese AI is catching up, posing a dilemma for Donald Trump

The success of cheap Chinese models threatens America’s technological lead


America has an imperial presidency

And in Donald Trump, an imperialist president for the first time in over a century

Tariffs will harm America, not induce a manufacturing rebirth

Donald Trump’s pursuit of tariffs will make the world poorer—and America, too 

How to improve clinical trials

Involving more participants can lead to new medical insights